The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study

Circulation

Volumn 128, Issue 3, 2013, Pages 237-243

  Connolly, Stuart J ^a   Wallentin, Lars ^b   Ezekowitz, Michael D ^o   Eikelboom, John ^a   Oldgren, Jonas ^b   Reilly, Paul A ^c   Brueckmann, Martina ^d,e   Pogue, Janice ^a   Alings, Marco ^f   Amerena, John V ^g   Avezum, Alvaro ^h   Baumgartner, Iris ⁱ   Budaj, Andrzej J ^j   Chen, Jyh Hong ^k   Dans, Antonio L ^l   Darius, Harald ^m   Di Pasquale, Giuseppe ⁿ   Ferreira, Jorge ^p   Flaker, Greg C ^q   Flather, Marcus D ^r   Franzosi, Maria Grazia ^s   Golitsyn, Sergey P ^t   Halon, David A ^u   Heidbuchel, Hein ^v   Hohnloser, Stefan H ^w   Huber, Kurt ^x   Jansky, Petr ^y   Kamensky, Gabriel ^z   Keltai, Matyas ^aa   Kim, Sung Soon ^ab   Lau, Chu Pak ^ac   Le Heuzey, Jean Yves ^ad   Lewis, Basil S ^v   Liu, Lisheng ^ae   Nanas, John ^af   Omar, Razali ^ag   Pais, Prem ^ah   Pedersen, Knud E ^ai   Piegas, Leopoldo S ^h   Raev, Dimitar ^aj   Smith, Pal J ^ak   Talajic, Mario ^al   Tan, Ru San ^am   Tanomsup, Supachai ^an   Toivonen, Lauri ^ao   Vinereanu, Dragos ^ap   Xavier, Denis ^ai   Zhu, Jun ^ae   Wang, Susan Q ^c   Duffy, Christine O ^c   Themeles, Ellison ^a   Yusuf, Salim ^a   more..

^a HAMILTON HEALTH SCIENCES   (Canada)

^b UPPSALA UNIVERSITY   (Sweden)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f AMPHIA HOSPITAL   (Netherlands)

^g DEAKIN UNIVERSITY   (Australia)

^h INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

ⁱ BERN UNIVERSITY HOSPITAL   (Switzerland)

^j GROCHOWSKI HOSPITAL   (Poland)

^k NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^l UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^m Vivantes Neukoelln Medical Center   (Germany)

ⁿ MAGGIORE HOSPITAL   (Italy)

^o LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^p HOSPITAL DE SANTA CRUZ   (Portugal)

^q UNIVERSITY OF MISSOURI   (United States)

^r ROYAL BROMPTON HOSPITAL   (United Kingdom)

^s MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^t INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^u CARMEL MEDICAL CENTER   (Israel)

^v UNIVERSITY OF LEUVEN   (Belgium)

^w GOETHE UNIVERSITY   (Germany)

^x WILHELMINEN HOSPITAL   (Austria)

^y UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^z UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^aa SEMMELWEIS UNIVERSITY   (Hungary)

^ab Yonsei University College of Medicine   (South Korea)

^ac UNIVERSITY OF HONG KONG   (Hong Kong)

^ad HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^ae FUWAI HOSPITAL   (China)

^af UNIVERSITY OF ATHENS   (Greece)

^ag NATIONAL HEART INSTITUTE   (Malaysia)

^ah ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^ai ODENSE UNIVERSITY HOSPITAL   (Denmark)

^aj MINISTRY OF THE INTERIOR   (Bulgaria)

^ak AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^al MONTREAL HEART INSTITUTE   (Canada)

^am DEPARTMENT OF CARDIOLOGY   (Singapore)

^an MAHIDOL UNIVERSITY   (Thailand)

^ao HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^ap CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

more..

Author keywords

Atrial fibrillation; Dabigatran; Hemorrhage; Stroke

Indexed keywords

DABIGATRAN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DYSPEPSIA; EMBOLISM; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC DISEASE;

ATRIAL FIBRILLATION; DABIGATRAN; HEMORRHAGE; STROKE;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; STROKE; TREATMENT OUTCOME;

EID: 84880370076     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.001139     Document Type: Article

References (9)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: A Report of the American College of Cardiology Committee for Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee t Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) [published correction appears in J Am Coll Cardiol. 2007;50:562.]. J Am Coll Cardiol. 2006;48:854-906.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
3. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070-1074.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361: 1139-1151.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363: 1875-1876.
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
8. Beasley BN, Unger EF, Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364:1788-1790.
9. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272-1274.